Stavudine

Active ingredient: Stavudine

In short: Stavudine capsules, in combination with other antiretroviral agents, are indicated for the treatment of human immunodeficiency virus (HIV)-1 infection .

Forms & strengthsThe 15 mg capsules have a hard-shell gelatin capsule with an off-white opaque cap and a pink opaque body filled with a white to off-white powder. The capsule is axially printed with M 154 in black ink on both the cap and body. …
LabelState of Florida DOH Central Pharmacy
Label updatedApr 15, 2014

What is Stavudine used for?

Stavudine capsules, in combination with other antiretroviral agents, are indicated for the treatment of human immunodeficiency virus (HIV)-1 infection .

âš  Boxed warning (FDA's strongest warning)

Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination, including stavudine and other antiretrovirals. Fatal lactic acidosis has been reported in pregnant women who received the combination of stavudine and didanosine with other antiretroviral agents. The combination of stavudine and didanosine should be used with caution during pregnancy and is recommended only if the potential benefit clearly outweighs the potential risk .

Fatal and nonfatal pancreatitis have occurred during therapy when stavudine was part of a combination regimen that included didanosine in both treatment-naive and treatment-experienced patients, regardless of degree of immunosuppression .

Stavudine dosage

The interval between doses of stavudine capsules should be 12 hours. Stavudine capsules may be taken with or without food.

The recommended adult dosage is based on body weight as follows:

For patients weighing less than 60 kg: 30 mg every 12 hours.

For patients weighing at least 60 kg: 40 mg every 12 hours.

For newborns from birth to 13 days old: 0.5 mg/kg given every 12 hours.

For pediatric patients at least 14 days old and weighing less than 30 kg: 1 mg/kg given every 12 hours.

For pediatric patients weighing at least 30 kg: use the recommended adult dosage.

Stavudine capsules may be administered to adult patients with impaired renal function with an adjustment in dosage as shown in Table 1.

Creatinine Clearance

(mL/min) | Recommended Stavudine Dose by Patient Weight

at least 60 kg | less than 60 kg

greater than 50 | 40 mg every 12 hours | 30 mg every 12 hours

26 to 50 | 20 mg every 12 hours | 15 mg every 12 hours

10 to 25 | 20 mg every 24 hours | 15 mg every 24 hours

Hemodialysis | 20 mg every 24 hoursAdministered after the completion of hemodialysis on dialysis days and at the same time of day on non-dialysis days. | 15 mg every 24 hours

Since urinary excretion is also a major route of elimination of stavudine in pediatric patients, the clearance of stavudine may be altered in children with renal impairment. There are insufficient data to recommend a specific dose adjustment of stavudine capsules in this patient population.

How to take Stavudine — instructions & advice from the label

See MEDICATION GUIDE.

Patients should be advised that stavudine capsules are not a cure for HIV-1 infection, and that they may continue to experience illnesses associated with HIV-1 infection, including opportunistic infections. Patients should be advised to remain under the care of a physician when using stavudine capsules and the importance of adherence to any antiretroviral regimen including those that contain stavudine capsules.

Patients should be advised to avoid doing things that can spread HIV-1 infection to others.

Do not share needles or other injection equipment.

Do not share personal items that can have blood or body fluids on them, like toothbrushes and razor blades.

Do not have any kind of sex without protection. Always practice safe sex by using a latex or polyurethane condom or other barrier method to lower the chance of sexual contact with semen, vaginal secretions or blood.

Do not breast-feed. It is not known if stavudine can be passed to your baby in your breast milk and whether it could harm your baby. Also, mothers with HIV-1 should not breast-feed because HIV-1 can be passed to the baby in breast milk. …

Warnings & precautions

Do not take this medicine if: Stavudine capsules are contraindicated in patients with clinically significant hypersensitivity to stavudine or to any of the components contained in the formulation.

Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination, including stavudine and other antiretrovirals. Although relative rates of lactic acidosis have not been assessed in prospective well controlled trials, longitudinal cohort and retrospective studies suggest that this infrequent event may be more often associated with antiretroviral combinations containing stavudine. Female gender, obesity and prolonged nucleoside exposure may be risk factors. Fatal lactic acidosis has been reported in pregnant women who received the combination of stavudine and didanosine with other antiretroviral agents. The combination of stavudine and didanosine should be used with caution during pregnancy and is recommended only if the potential benefit clearly outweighs the potential risk .

Particular caution should be exercised when administering stavudine to any patient with known risk factors for liver disease; however, cases of lactic acidosis have also been reported in patients with no known risk factors. Generalized fatigue, digestive symptoms (nausea, vomiting, abdominal pain and unexplained weight loss); respiratory symptoms (tachypnea and dyspnea); or neurologic symptoms, including motor weakness might be indicative of the development of symptomatic hyperlactatemia or lactic acidosis syndrome.

Treatment with stavudine should be suspended in any patient who develops clinical or laboratory findings suggestive of symptomatic hyperlactatemia, lactic acidosis or pronounced hepatotoxicity (which may include hepatomegaly and steatosis even in the absence of marked transaminase elevations). …

Stavudine side effects

The following adverse reactions are discussed in greater detail in other sections of the labeling:

lactic acidosis and severe hepatomegaly with steatosis

hepatic toxicity

neurologic symptoms and motor weakness

pancreatitis

lipoatrophy/lipodystrophy

When stavudine is used in combination with other agents with similar toxicities, the incidence of adverse reactions may be higher than when stavudine is used alone.

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Selected adverse reactions that occurred in adult patients receiving stavudine in a controlled monotherapy study (Study AI455-019) are provided in Table 2.

Adverse Reaction | Percent (%)

StavudineMedian duration of stavudine therapy = 79 weeks; median duration of zidovudine therapy = 53 weeks

(40 mg twice daily)

(n = 412) | Zidovudine

(200 mg 3 times daily)

(n = 402)

Headache | 54 | 49

Diarrhea | 50 | 44

Peripheral Neurologic

Symptoms/Neuropathy | 52 | 39

Rash | 40 | 35

Nausea and Vomiting | 39 | 44

Pancreatitis was observed in three of the 412 adult patients who received stavudine in study AI455-019.

Selected adverse reactions that occurred in antiretroviral-naive adult patients receiving stavudine from two controlled combination studies are provided in Table 3. …

Drug interactions

Stavudine is unlikely to interact with drugs metabolized by cytochrome P450 isoenzymes.

Zidovudine:

Zidovudine competitively inhibits the intracellular phosphorylation of stavudine. Therefore, use of zidovudine in combination with stavudine should be avoided.

Doxorubicin:

In vitro data indicate that the phosphorylation of stavudine is inhibited at relevant concentrations by doxorubicin. The clinical significance of this interaction is unknown; therefore, concomitant use of stavudine with doxorubicin should be undertaken with caution.

Ribavirin:

In vitro data indicate ribavirin reduces phosphorylation of lamivudine, stavudine and zidovudine. The clinical significance of the interaction with stavudine is unknown; therefore, concomitant use of stavudine with ribavirin should be undertaken with caution. No pharmacokinetic (e.g., plasma concentrations or intracellular triphosphorylated active metabolite concentrations) or pharmacodynamic (e.g., loss of HIV-1/HCV virologic suppression) interaction was observed when ribavirin and lamivudine (n = 18), stavudine (n = 10) or zidovudine (n = 6) were coadministered as part of a multi-drug regimen to HIV-1/HCV co-infected patients .

About this medicine

Stavudine (d4T) is a synthetic thymidine nucleoside analogue, active against the human immunodeficiency virus type 1 (HIV-1). The chemical name for stavudine is 2',3'-didehydro-3'-deoxythymidine. Stavudine has the following structural formula:

Stavudine, USP is a white to off-white crystalline solid with the molecular formula C10H12N2O4 and a molecular weight of 224.21. The solubility of stavudine at 23°C is approximately 83 mg/mL in water and 30 mg/mL in propylene glycol. The n-octanol/water partition coefficient of stavudine at 23°C is 0.144.

Stavudine Capsules, USP are supplied for oral administration in strengths of 15 mg, 20 mg, 30 mg or 40 mg of stavudine, USP. Each capsule also contains inactive ingredients: lactose anhydrous, magnesium stearate, microcrystalline cellulose and sodium starch glycolate. The empty hard shell gelatin capsules contain gelatin and titanium dioxide. In addition, the 15 mg empty capsules contain D&C Red No. 28, D&C Yellow No. 10, FD&C Blue No. 1, FD&C Red No. 40, FD&C Yellow No. 6; the 20 mg empty capsules contain D&C Red No. 28, FD&C Blue No. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 7501de1e-149d-405e-94f6-da4010952adf. Read the full official label on DailyMed.